NASDAQ:ANGO - AngioDynamics Stock Price, Price Target & More

Get Started

$20.13 -0.13 (-0.64 %)

(As of 05/23/2018 05:16 AM ET)

Previous Close$20.26

Today's Range$19.91 - $20.31

52-Week Range$14.97 - $20.71

Volume270,100 shs

Average Volume164,104 shs

Market Capitalization$745.66 million

P/E Ratio28.14

Dividend YieldN/A

Beta1.01

About AngioDynamics (NASDAQ:ANGO)

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:ANGO

CUSIP03475V10

Webwww.angiodynamics.com

Phone518-795-1400

Debt

Debt-to-Equity Ratio0.16

Current Ratio2.88

Quick Ratio1.84

Price-To-Earnings

Trailing P/E Ratio28.14

Forward P/E Ratio27.20

P/E Growth1.83

Sales & Book Value

Annual Sales$349.64 million

Price / Sales2.12

Cash Flow$1.4008 per share

Price / Cash14.37

Book Value$14.00 per share

Price / Book1.44

Profitability

EPS (Most Recent Fiscal Year)$0.73

Net Income$5 million

Net Margins0.97%

Return on Equity5.11%

Return on Assets3.81%

Miscellaneous

Employees1,250

Outstanding Shares36,810,000

AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Thursday, March, 29th. The medical instruments supplier reported $0.25 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.20 by $0.05. The medical instruments supplier had revenue of $83.85 million for the quarter, compared to analyst estimates of $86.13 million. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%. View AngioDynamics' Earnings History.

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release their next quarterly earnings announcement on Monday, July, 16th 2018. View Earnings Estimates for AngioDynamics.

What price target have analysts set for ANGO?

7 equities research analysts have issued 12 month price targets for AngioDynamics' shares. Their predictions range from $16.00 to $21.00. On average, they anticipate AngioDynamics' share price to reach $17.5825 in the next year. View Analyst Ratings for AngioDynamics.

Who are some of AngioDynamics' key competitors?

Some companies that are related to AngioDynamics include Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), CryoLife (CRY), Cardiovascular Systems (CSII) and K2M Group (KTWO).

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the folowing people:

Mr. James C. Clemmer, Pres, CEO & Director (Age 54)
Mr. Michael C. Greiner, Exec. VP, CFO & Principal Accounting Officer (Age 45)
Mr. Stephen A. Trowbridge, Sr. VP, Gen. Counsel & Assistant Sec. (Age 44)
Mr. Chad T. Campbell, Sr. VP & Gen. Mang. of Global Vascular Access (Age 47)
Mr. Robert A. Simpson, Sr. VP Peripheral Vascular (Age 46)

Has AngioDynamics been receiving favorable news coverage?

Headlines about ANGO stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AngioDynamics earned a news impact score of 0.15 on Accern's scale. They also assigned press coverage about the medical instruments supplier an impact score of 46.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.87%), Dimensional Fund Advisors LP (8.40%), Wells Fargo & Company MN (3.30%), Fort Washington Investment Advisors Inc. OH (2.79%), JPMorgan Chase & Co. (2.43%) and Segall Bryant & Hamill LLC (1.77%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, David F Burgstahler, James C Clemmer and Jan Stern Reed. View Institutional Ownership Trends for AngioDynamics.

Which major investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Systematic Financial Management LP, American Century Companies Inc., Schwab Charles Investment Management Inc., Spark Investment Management LLC, Prudential Financial Inc., California Public Employees Retirement System, Russell Investments Group Ltd. and Lapides Asset Management LLC. View Insider Buying and Selling for AngioDynamics.

Which major investors are buying AngioDynamics stock?

ANGO stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Segall Bryant & Hamill LLC, BlackRock Inc., Heartland Advisors Inc., Millennium Management LLC, Fort Washington Investment Advisors Inc. OH, Wells Fargo & Company MN and Mackay Shields LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $20.13.

How big of a company is AngioDynamics?

AngioDynamics has a market capitalization of $745.66 million and generates $349.64 million in revenue each year. The medical instruments supplier earns $5 million in net income (profit) each year or $0.73 on an earnings per share basis. AngioDynamics employs 1,250 workers across the globe.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]

MarketBeat Community Rating for AngioDynamics (ANGO)

Community Ranking:		2.0 out of 5 ( )
Outperform Votes:		188 (Vote Outperform)
Underperform Votes:		273 (Vote Underperform)
Total Votes:		461

MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.

AngioDynamics (NASDAQ:ANGO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for AngioDynamics in the last 12 months. Their average twelve-month price target is $17.5825, suggesting that the stock has a possible downside of 12.66%. The high price target for ANGO is $21.00 and the low price target for ANGO is $16.00. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.43	2.43	2.20	2.40
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$17.5825	$17.5825	$18.50	$18.50
Price Target Upside:	12.66% downside	6.97% downside	17.76% upside	8.63% upside

AngioDynamics (NASDAQ:ANGO) Consensus Price Target History

Price Target History for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/3/2018	Raymond James	Upgrade	Market Perform ➝ Outperform	$16.33	Medium
4/3/2018	UBS	Upgrade	Market Perform ➝ Outperform		Medium
4/2/2018	Canaccord Genuity	Boost Price Target	Hold ➝ Hold	$16.50 ➝ $17.00	Low
1/5/2018	Craig Hallum	Downgrade	Buy ➝ Hold		High
9/29/2017	KeyCorp	Reiterated Rating	Hold		High
7/19/2017	Barclays	Lower Price Target	Equal Weight	$17.00 ➝ $16.00	Low
7/4/2017	Cantor Fitzgerald	Boost Price Target	Overweight	$20.00 ➝ $21.00	Low

(Data available from 5/23/2016 forward)

AngioDynamics (NASDAQ:ANGO) Earnings History and Estimates Chart

Earnings by Quarter for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO) Earnings Estimates

2018 EPS Consensus Estimate: $0.74

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.14	$0.18	$0.16
Q2 2018	2	$0.15	$0.16	$0.16
Q3 2018	2	$0.20	$0.23	$0.22
Q4 2018	2	$0.15	$0.26	$0.21

AngioDynamics (NASDAQ ANGO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/16/2018		$0.21					N/A
3/29/2018	Q3 2018	$0.20	$0.25	$86.13 million	$83.85 million	View	Listen
1/4/2018	Q2 2018	$0.16	$0.16	$88.15 million	$86.70 million	View	Listen
9/28/2017	Q1 2018	$0.16	$0.12	$86.12 million	$85.40 million	View	N/A
7/18/2017	Q4 2017	$0.16	$0.19	$90.72 million	$86.90 million	View	N/A
3/30/2017	Q3 2017	$0.15	$0.19	$88.29 million	$85.60 million	View	N/A
1/6/2017	Q217	$0.16	$0.19	$91.09 million	$89.00 million	View	Listen
10/5/2016	Q117	$0.13	$0.17	$86.09 million	$88.10 million	View	N/A
7/13/2016	Q416	$0.16	$0.19	$88.64 million	$93.40 million	View	Listen
4/7/2016	Q3	$0.14	$0.15	$85.43 million	$87.40 million	View	Listen
1/7/2016	Q216	$0.14	$0.14	$88.67 million	$89.20 million	View	N/A
10/8/2015	Q116	$0.11	$0.11	$84.70 million	$83.70 million	View	N/A
7/16/2015	Q415	$0.14	$0.14	$91.67 million	$90.90 million	View	Listen
4/9/2015	Q315	$0.15	$0.12	$88.69 million	$86.60 million	View	N/A
1/8/2015	Q215	$0.15	$0.17	$90.90 million	$92.10 million	View	N/A
10/9/2014	Q115	$0.11	$0.16	$85.35 million	$87.30 million	View	Listen
7/23/2014	Q414	$0.12	$0.18	$93.65 million	$94.07 million	View	Listen
4/9/2014	Q314	$0.09	$0.16	$86.85 million	$88.20 million	View	Listen
1/9/2014	Q2	$0.07	$0.14	$87.54 million	$88.60 million	View	Listen
10/10/2013	Q114	$0.03	$0.04	$82.54 million	$83.60 million	View	N/A
7/11/2013	Q4 2013	$0.06	$0.07	$86.43 million	$90.00 million	View	N/A
4/8/2013	Q3 2013	$0.05	$0.08	$81.70 million	$81.60 million	View	N/A
1/3/2013	Q2 2013	$0.09	$0.10	$87.40 million	$87.00 million	View	N/A
10/8/2012	Q113	$0.09	$0.10	$84.35 million	$83.40 million	View	N/A
7/12/2012		$0.08	$0.09			View	N/A
4/4/2012		$0.07	$0.09			View	N/A
1/5/2012		$0.12	$0.13			View	N/A
10/6/2011		$0.09	$0.08			View	N/A
7/14/2011		$0.10	$0.11			View	N/A
4/5/2011		$0.12	$0.15			View	N/A
1/4/2011		$0.12	$0.13			View	N/A
10/7/2010	Q1 2011	$0.08	$0.08			View	N/A
7/15/2010	Q4 2010	$0.13	$0.15			View	N/A
3/31/2010	Q3 2010	$0.12	$0.13			View	N/A
1/5/2010	Q2 2010	$0.11	$0.13			View	N/A
10/6/2009	Q1 2010	$0.08	$0.09			View	N/A
7/16/2009	Q4 2009	$0.15	$0.14			View	N/A
4/2/2009	Q3 2009	$0.12	$0.15			View	N/A
1/6/2009	Q2 2009	$0.12	$0.12			View	N/A
10/2/2008	Q1 2009	$0.11	$0.09			View	N/A
7/24/2008	Q4 2008	$0.17	$0.20			View	N/A
4/2/2008	Q3 2008	$0.13	$0.14			View	N/A
1/3/2008	Q2 2008	$0.13	$0.13			View	N/A

(Earnings results data provided by Zacks Investment Research)

AngioDynamics (NASDAQ:ANGO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

AngioDynamics (NASDAQ ANGO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 97.62%

Insider Trading History for AngioDynamics (NASDAQ:ANGO)

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ ANGO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/24/2017	Jan Stern Reed	Director	Buy	316	$16.00	$5,056.00	316
7/21/2017	James C Clemmer	CEO	Buy	5,000	$15.79	$78,950.00	86,683
7/20/2017	James C Clemmer	CEO	Buy	20,000	$15.64	$312,800.00	86,683
4/12/2017	Avista Capital Partners Gp, Ll	Major Shareholder	Sell	2,350,000	$16.00	$37,600,000.00
8/5/2016	Avista Capital Partners Gp, Ll	Major Shareholder	Sell	2,241,000	$14.62	$32,763,420.00
8/5/2016	David F Burgstahler	Director	Sell	2,250,000	$14.62	$32,895,000.00	23,988
5/6/2016	Charles R Greiner	VP	Sell	3,508	$12.31	$43,183.48	20,910
4/25/2016	Stephen A Trowbridge	SVP	Sell	12,940	$12.30	$159,162.00	32,469
4/14/2014	Matthew Kapusta	SVP	Buy	1,000	$13.90	$13,900.00	27,005
10/18/2013	Vincent Bucci	Director	Buy	5,000	$15.20	$76,000.00
10/17/2013	Howard W Donnelly	Director	Sell	20,000	$15.06	$301,200.00
7/22/2013	Kevin J Gould	Director	Buy	2,700	$12.00	$32,400.00
5/9/2013	Charles R Greiner	VP	Sell	1,495	$10.38	$15,518.10
3/12/2013	Vincent Bucci	Director	Buy	85,000	$10.77	$915,450.00
2/14/2013	Vincent Bucci	Director	Buy	2,000	$12.17	$24,340.00
1/11/2013	Kevin J Gould	Director	Buy	2,700	$11.58	$31,266.00
11/5/2012	Jeffrey Gold	Director	Buy	1,000	$10.56	$10,560.00

(Data available from 1/1/2013 forward)

AngioDynamics (NASDAQ ANGO) News Headlines

Source:

Date	Headline
	Global Vascular Access Devices Market Growth Opportunities: Edwards Lifesciences Corporation, AngioDynamics, Becton www.marketwatch.com - May 22 at 9:10 AM
	AngioDynamics, Inc. (ANGO) Expected to Announce Quarterly Sales of $88.99 Million www.americanbankingnews.com - May 16 at 5:01 AM
	AngioDynamics (ANGO) vs. Obalon Therapeutics (OBLN) Financial Review www.americanbankingnews.com - May 15 at 12:29 PM
	AngioDynamics, Inc. (ANGO) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - May 14 at 5:16 PM
	Brokerages Anticipate AngioDynamics, Inc. (ANGO) to Post $0.21 EPS www.americanbankingnews.com - May 14 at 1:17 AM
	Why Is AngioDynamics (ANGO) Up 13.9% Since Its Last Earnings Report? finance.yahoo.com - April 30 at 9:28 AM
	$88.99 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter www.americanbankingnews.com - April 28 at 3:04 AM
	Global Tumor Ablation Market Competitive landscape: LLC., Boston Scientific Corporation, AngioDynamics www.marketwatch.com - April 27 at 9:48 AM
	Brokerages Expect AngioDynamics, Inc. (ANGO) Will Announce Earnings of $0.21 Per Share www.americanbankingnews.com - April 26 at 1:26 PM
	AngioDynamics (ANGO) & Its Peers Head to Head Comparison www.americanbankingnews.com - April 24 at 11:02 PM
	Global Varicose Vein Treatment Market Overview 2017-2026: Sciton Inc, Energist Ltd, AngioDynamics Inc www.marketwatch.com - April 24 at 9:16 AM
	AngioDynamics (ANGO) Price Target Increased to $21.00 by Analysts at Cantor Fitzgerald www.americanbankingnews.com - April 19 at 11:52 PM
	AngioDynamics, Inc. (ANGO) Given Average Recommendation of "Buy" by Analysts www.americanbankingnews.com - April 19 at 5:40 PM
	AngioDynamics (ANGO) Upgraded to B- by TheStreet www.americanbankingnews.com - April 18 at 10:41 AM
	AngioDynamics (ANGO) Downgraded by BidaskClub www.americanbankingnews.com - April 14 at 6:23 PM
	AngioDynamics to Present at Two Investor Conferences in May finance.yahoo.com - April 10 at 4:36 PM
	AngioDynamics (ANGO) Raised to Strong-Buy at BidaskClub www.americanbankingnews.com - April 10 at 11:28 AM
	Zacks: Brokerages Expect AngioDynamics, Inc. (ANGO) to Announce $0.21 EPS www.americanbankingnews.com - April 9 at 3:21 PM
	AngioDynamics (ANGO) Upgraded to "Buy" by Zacks Investment Research www.americanbankingnews.com - April 8 at 10:49 AM
	AngioDynamics (ANGO) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 6 at 11:38 AM
	Blog Exposure - Waters Corp. to Significantly Expand its Precision Chemistry Facility in Massachusetts finance.yahoo.com - April 5 at 4:33 PM
	AngioDynamics (ANGO) Product Line Strong, Debt Level High finance.yahoo.com - April 3 at 4:37 PM
	Raymond James Financial Upgrades AngioDynamics (ANGO) to Outperform www.americanbankingnews.com - April 3 at 10:43 AM
	AngioDynamics (ANGO) Upgraded at UBS www.americanbankingnews.com - April 3 at 7:48 AM
	AngioDynamics (ANGO) PT Raised to $17.00 at Canaccord Genuity www.americanbankingnews.com - April 2 at 2:38 PM
	AngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates View www.zacks.com - April 2 at 9:47 AM
	AngioDynamics (ANGO) Q3 2018 Earnings Conference Call Transcript finance.yahoo.com - April 1 at 4:59 PM
	AngioDynamics (ANGO) Downgraded by TheStreet to C www.americanbankingnews.com - March 30 at 5:08 PM
	AngioDynamics (ANGO) Raised to Buy at BidaskClub www.americanbankingnews.com - March 30 at 1:06 PM
	Edited Transcript of ANGO earnings conference call or presentation 29-Mar-18 12:00pm GMT finance.yahoo.com - March 30 at 9:24 AM
	AngioDynamics (ANGO) Posts Earnings Results, Beats Expectations By $0.06 EPS www.americanbankingnews.com - March 30 at 7:52 AM
	Head to Head Survey: AngioDynamics (ANGO) vs. Its Peers www.americanbankingnews.com - March 30 at 3:06 AM
	AngioDynamics beats by $0.06, misses on revenue seekingalpha.com - March 29 at 4:35 PM
	AngioDynamics Q3 revenues down 2%; non-GAAP EPS up 32% seekingalpha.com - March 29 at 9:41 AM
	AngioDynamics misses 3Q revenue forecasts finance.yahoo.com - March 29 at 9:41 AM
	Where AngioDynamics Inc (NASDAQ:ANGO) Stands In Earnings Growth Against Its Industry finance.yahoo.com - March 29 at 9:41 AM
	AngioDynamics (ANGO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow seekingalpha.com - March 28 at 4:33 PM
	AngioDynamics, Inc. (ANGO) Receives Average Recommendation of "Hold" from Brokerages www.americanbankingnews.com - March 25 at 5:18 PM
	AngioDynamics (ANGO) Lifted to "Hold" at BidaskClub www.americanbankingnews.com - March 25 at 3:47 PM
	AngioDynamics, Inc. (ANGO) Expected to Announce Earnings of $0.20 Per Share www.americanbankingnews.com - March 23 at 3:17 PM
	Global Vascular Access Devices Market Opportunities 2018: R. Bard, Braun Melsungen AG, Dickinson and Company, AngioDynamics www.marketwatch.com - March 21 at 10:26 AM
	AngioDynamics (ANGO) Set to Announce Earnings on Wednesday www.americanbankingnews.com - March 21 at 1:36 AM
	AngioDynamics to Present at the Needham 17th Annual Healthcare Conference finance.yahoo.com - March 15 at 5:04 PM
	AngioDynamics, Inc. (ANGO) Expected to Announce Quarterly Sales of $86.13 Million www.americanbankingnews.com - March 8 at 7:54 AM
	$0.20 Earnings Per Share Expected for AngioDynamics, Inc. (ANGO) This Quarter www.americanbankingnews.com - March 6 at 9:42 AM
	Arrowstreet Capital Limited Partnership Purchases 29,400 Shares of AngioDynamics, Inc. (ANGO) www.americanbankingnews.com - March 6 at 4:35 AM
	Broadfin Capital LLC Has $28.81 Million Position in AngioDynamics, Inc. (ANGO) www.americanbankingnews.com - March 2 at 5:08 AM
	Spark Investment Management LLC Raises Stake in AngioDynamics, Inc. (ANGO) www.americanbankingnews.com - March 1 at 6:58 PM
	AngioDynamics, Inc. (ANGO) Shares Sold by Martingale Asset Management L P www.americanbankingnews.com - March 1 at 9:34 AM
	A Look at the Performances of Abaxis’s Product Categories finance.yahoo.com - March 1 at 9:04 AM

AngioDynamics (NASDAQ:ANGO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

AngioDynamics (NASDAQ:ANGO) Income Statement, Balance Sheet and Cash Flow Statement

AngioDynamics (NASDAQ ANGO) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff